Literature DB >> 8180109

The unliganded estrogen receptor (ER) transduces growth factor signals.

C J Newton1, R Buric, T Trapp, S Brockmeier, U Pagotto, G K Stalla.   

Abstract

In the absence of serum and estrogen, we show that the growth of the prolactin secreting pituitary tumour cell line, GH3 is stimulated by insulin and insulin-like growth factor-1 (IGF-1) and this response is blocked by the steroidal antiestrogens, ICI 164384 and ICI 182780. From conditioned medium (CM) experiments, growth of low density cells (10k/cm2) is increased by the addition of CM from high density cells (100k/cm2) and this growth effect is also blocked by antiestrogen. Transfection studies with a delta MTV-ERE-LUC reporter plasmid show that in the absence of estrogen and serum, both insulin and IGF-1 induce luciferase expression and this is blocked by the pure antiestrogens. No effect of these treatments was apparent when parallel experiments were conducted with a plasmid construct lacking the vitellogenin estrogen response element. From these and other data discussed in this report, we conclude that for GH3 cells, in the absence of estrogen and serum, the ER is transcriptionally activated by intracellular peptide factor pathways and by this means, acts as the key nuclear factor inducing mitogenesis in response to autocrine and exogenously added growth factors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8180109     DOI: 10.1016/0960-0760(94)90197-x

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  19 in total

1.  Influence of antiestrogens on EGF- and IGF-I-mediated proliferation of human breast cancer cells.

Authors:  G M Tong; T T Rajah; J T Pento
Journal:  In Vitro Cell Dev Biol Anim       Date:  1999-01       Impact factor: 2.416

2.  Epidermal growth factor receptor and tyrosine phosphorylation of estrogen receptor.

Authors:  D C Márquez; J Lee; T Lin; R J Pietras
Journal:  Endocrine       Date:  2001-11       Impact factor: 3.633

3.  Phosphorylation of human estrogen receptor alpha by protein kinase A regulates dimerization.

Authors:  D Chen; P E Pace; R C Coombes; S Ali
Journal:  Mol Cell Biol       Date:  1999-02       Impact factor: 4.272

4.  Discovery at the interface: Toward novel anti-proliferative agents targeting human estrogen receptor/S100 interactions.

Authors:  David H Lee; Bethany K Asare; Rajendram V Rajnarayanan
Journal:  Cell Cycle       Date:  2016-08-11       Impact factor: 4.534

Review 5.  Minireview: Tipping the balance: ligand-independent activation of steroid receptors.

Authors:  Marcela A Bennesch; Didier Picard
Journal:  Mol Endocrinol       Date:  2015-01-27

6.  Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation.

Authors:  G Bunone; P A Briand; R J Miksicek; D Picard
Journal:  EMBO J       Date:  1996-05-01       Impact factor: 11.598

Review 7.  Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines.

Authors:  A E Wakeling; A J Barker; D H Davies; D S Brown; L R Green; S A Cartlidge; J R Woodburn
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

8.  Silencing of estrogen receptor alpha in the ventromedial nucleus of hypothalamus leads to metabolic syndrome.

Authors:  Sergei Musatov; Walter Chen; Donald W Pfaff; Charles V Mobbs; Xue-Jun Yang; Deborah J Clegg; Michael G Kaplitt; Sonoko Ogawa
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-06       Impact factor: 11.205

Review 9.  Activation of the androgen receptor by polypeptide growth factors and cellular regulators.

Authors:  Z Culig; A Hobisch; M V Cronauer; A Hittmair; C Radmayr; G Bartsch; H Klocker
Journal:  World J Urol       Date:  1995       Impact factor: 4.226

10.  Comparison between novel steroid-like and conventional nonsteroidal antioestrogens in inhibiting oestradiol- and IGF-I-induced proliferation of human breast cancer-derived cells.

Authors:  A de Cupis; D Noonan; P Pirani; A Ferrera; L Clerico; R E Favoni
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.